Specifically, the KEYNOTE-189 trial demonstrated that the addition of pembrolizumab to chemotherapy, as first-line therapy, significantly improved both progression-free survival (PFS) and overall survival (OS) in NSCLC patients with metastatic disease, regardless of their PD-L1 status [33]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.